Sign up to save your podcasts
Or
Share IMforte - Maintenance Lurbinectedin + Atezo FDA Approval for Extensive Small Cell Lung Cancer (SCLC)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
IMforte - Maintenance Lurbinectedin + Atezo FDA Approval for Extensive Small Cell Lung Cancer (SCLC)
In this episode of the Oncology Brothers podcast, we dive deep into the latest advancements in treating extensive stage small cell lung cancer (SCLC), focusing on the IMforte data and its clinical implications. We welcomed esteemed thoracic medical oncologists Drs. Isabel Preeshagul, Ticiana Leal, and Dr. Stephen Liu to discuss the findings presented at ASCO 2025 and World Lung 2025.
Key topics included:
• Overview of the IMforte study design and patient population
• The role of lurbinectedin and atezolizumab as maintenance therapy
• Significant improvements in progression-free survival (PFS) and overall survival (OS)
• Management of side effects and the importance of prophylactic growth factors
• Patient selection criteria for this new standard of care
With a focus on bridging the gap between community and academia, this episode provides valuable insights for medical oncologists and patients alike. Tune in to learn how these advancements are changing the landscape of SCLC treatment and improving patient outcomes.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other discussions on recent approvals, treatment algorithms, and challenging cases. We are the Oncology Brothers!
#IMforte #SCLC #Lurbinectedin #MaintenanceTherapy #ASCO2025 #OncologyBrothers #ES-SCLC
View all episodes
By Oncology Brothers
4.8
3939 ratings
In this episode of the Oncology Brothers podcast, we dive deep into the latest advancements in treating extensive stage small cell lung cancer (SCLC), focusing on the IMforte data and its clinical implications. We welcomed esteemed thoracic medical oncologists Drs. Isabel Preeshagul, Ticiana Leal, and Dr. Stephen Liu to discuss the findings presented at ASCO 2025 and World Lung 2025.
Key topics included:
• Overview of the IMforte study design and patient population
• The role of lurbinectedin and atezolizumab as maintenance therapy
• Significant improvements in progression-free survival (PFS) and overall survival (OS)
• Management of side effects and the importance of prophylactic growth factors
• Patient selection criteria for this new standard of care
With a focus on bridging the gap between community and academia, this episode provides valuable insights for medical oncologists and patients alike. Tune in to learn how these advancements are changing the landscape of SCLC treatment and improving patient outcomes.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other discussions on recent approvals, treatment algorithms, and challenging cases. We are the Oncology Brothers!
#IMforte #SCLC #Lurbinectedin #MaintenanceTherapy #ASCO2025 #OncologyBrothers #ES-SCLC
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
JAMA Editors' Summary
136 Listeners
NEJM This Week
323 Listeners
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
116 Listeners
JAMA Clinical Reviews
501 Listeners
ASCO Daily News
57 Listeners
JAMA Medical News
87 Listeners
Core IM | Internal Medicine Podcast
1,141 Listeners
The ONS Podcast
201 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
The Clinical Problem Solvers
514 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners